Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy
Age-related macular degeneration (AMD) is a prevalent cause of vision loss among individuals over the age of 65 globally. Over 18 million people in the United States alone are estimated to have milder forms of AMD, with a substantial portion
The post Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy first appeared on TechStartups.
Age-related macular degeneration (AMD) is a prevalent cause of vision loss among individuals over the age of 65 globally. Over 18 million people in the United States alone are estimated to have milder forms of AMD, with a substantial portion […]
The post Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy first appeared on TechStartups.